A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
Xiuning Le*, Jyoti D. Patel, Elaine Shum, Christina Baik, Rachel E. Sanborn, Catherine A. Shu, Chul Kim, Mary Jo Fidler, Richard Hall, Yasir Y. Elamin, Janet Tu, George Blumenschein, Jianjun Zhang, Don Gibbons, Carl Gay, Nisha A. Mohindra, Young Chae, Yanis Boumber, Joshua Sabari, Rafael Santana-DavilaShane Rogosin, Benjamin Herzberg, Ben Creelan, Bruna Pellini, Tawee Tanvetyanon, Simon Heeke, Mike Hernandez, Jhanelle E. Gray, Andreas Saltos, John V. Heymach
Dive into the research topics of 'A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)'. Together they form a unique fingerprint.